-
[show abstract]
[hide abstract]
ABSTRACT: A signal-enhanced label-free electrochemical immunosensor was constructed by the employment of Prussian blue doped silica dioxide (PB-SiO2) nanocomposite. At first, PB-SiO2 nanocomposite which was produced by using a microemulsion method was used to obtain a nanostructural monolayer on a glassy carbon electrode (GCE) surface. Next amino-functionalized interface were prepared by self-assembling 3-aminopropyltriethoxy silane (APTES) on the PB-SiO2 nanoparticle surface. Then chitosan stabled gold nanoparticle (CS-nanoAu) was subsequently attached, while the entire surface was finally loaded with neuron-specific enolase antibody (anti-NSE) via the adsorption of gold nanoparticle. The sensitivity of the proposed immunosensor has greatly improved as the PB-SiO2 nanostructural sensing film provides plenty of active sites which might catalyze the reduction of H2O2. The immunosensor exhibited good linear behavior in the concentration range from 0.25–5.0 and 5.0–75 ng/mL for the quantitative analysis of neuron-specific enolase (NSE), a putative serum marker of small-cell lung carcinoma (SCLC), with a limit of detection of 0.08 ng/mL. The resulting NSE immunosensor showed high sensitivity and long-term lifetime which can be attributed to the extremely high catalytic activity and biocompatibility of CS-nanoAu/APTES/PB-SiO2 nanostructural multilayers.
Electroanalysis 08/2010; 22(21):2569 - 2575. · 2.87 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: A new, highly sensitive electrochemical immunosensor with a sandwich-type immunoassay format was designed to quantify carcinoembryonic antigen (CEA), as a model tumor marker, using nanogold-enwrapped graphene nanocomposites (NGGNs) as trace labels in clinical immunoassays. The device consisted of a glassy carbon electrode coated with Prussian Blue (PB) on whose surface gold nanoparticles were electrochemically deposited to the further modified with the specific analyte-capturing molecule, anti-CEA antibodies. The immunoassay was performed using horseradish peroxidase (HRP)-conjugated anti-CEA as secondary antibodies attached on the NGGN surface (HRP-anti-CEA-NGGN). The method using HRP-anti-CEA-NGGNs as detection antibodies shows high signal amplification, and exhibits a dynamic working range of 0.05-350 ng/mL with a low detection limit of 0.01 ng/mL CEA (at 3s). The assayed results of serum samples with the sensor received an acceptable agreement with the reference values. Importantly, the methodology provides a promising ultrasensitive assay strategy for clinical applications.
Biosensors & bioelectronics 03/2010; 25(10):2379-83. · 5.43 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Antiangiogenesis has become the fourth module of cancer therapy nowadays. However, its clinical effect varies from cancer to cancer. The aim of this study is to compare the clinical efficacy of rh-endostatin (YH-16, Endostar) on retreated non-small cell lung cancer and colorectal cancer.
The patients including 17 cases of retreated non-small cell lung cancer (NSCLC) and 15 cases of retreated colorectal cancer were confirmed by histopathology or cytopathology. All the cases were administrated with rh-endostatin combining chemotherapy and radiotherapy. 7.5 mg/m(2) rhendostatin solved in 500 mL of normal saline was slow intravenously dropped from day 1 to day 14. The efficacy was evaluated strictly according to RECIST criteria and the quality of life (QOL) was based on the Karnofsky performance (KPS).
The response rate (RR) of 17 cases of retreated NSCLC was 11.8% (2/17), and the disease control rate (DCR) was 41.2% (7/17). However, the RR and DCR of the 15 cases of retreated colorectal cancer were up to 40% (6/15) and 86.6% (13/15). There was significant difference between these two tumors (P<0.05). Moreover, significant difference was also found on the QOL of these two tumors [The improving and stable QOL was 41.2% (7/17) and 86.6% (13/15), respectively (P<0.05)].
The clinical efficacy of rh-endostatin on retreated colorectal cancer was better than on retreated non-small cell lung cancer, which suggested that it was necessary to perform more clinical observations on the digestive tumors.
Zhongguo fei ai za zhi = Chinese journal of lung cancer 11/2009; 12(11):1184-7.
